FDA Approved: CRYSVITA — Supplemental Application (Kyowa Kirin, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for CRYSVITA (burosumab) submitted by Kyowa Kirin, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• X-linked Hypophosphatemia

Drugs mentioned

• Crysvita (burosumab)

Snippet

SUPPL AP for CRYSVITA (BUROSUMAB)